Brands
Biocon names Shreehas Tambe CEO as Siddharth Mittal exits corner office
Leadership rejig aligns with biologics integration and wider organisational overhaul
BENGALURU: Biocon is resetting its leadership deck just as it redraws its business architecture. The Bengaluru-based biopharma firm has named Shreehas Tambe as chief executive officer and managing director, replacing Siddharth Mittal, who is stepping down from the role at the end of March.
The board approved the transition on March 27, following Mittal’s resignation on March 20. He will exit as ceo and managing director, and as key managerial personnel, at the close of business on March 31, 2026, before moving into another leadership role within the Biocon group.
Tambe, currently a senior leader within the group, will take charge from April 1 for a five-year term, subject to shareholder approval. He will also join the board as an additional director from the same date.
The leadership switch comes as Biocon folds Biocon Biologics into the parent, creating a unified structure spanning biosimilars and generics—a move aimed at sharpening scale and execution in a competitive global market.
The reshuffle runs deeper. Interim chief financial officer Mukesh Kamath will step down on March 31 to take up another group role, with Kedar Upadhye stepping in as cfo from April 1. Akhilesh Nand has been named head of governance, risk and compliance and key managerial personnel, while Naveen Narayanan will take over as chief human resources officer and Mandar Shrikant Ghatnekar as chief technology officer.
Kiran Mazumdar-Shaw, executive chairperson, framed the transition as a strategic pivot. The integration, she said, positions Biocon as a “globally scaled biopharma enterprise”. She credited Tambe with steering key milestones, including the acquisition and integration of the Viatris biosimilars business, and acknowledged Mittal’s role in shaping the company’s growth since 2013.
Tambe called the appointment an “honor and privilege”, signalling a focus on consolidating operations, strengthening the foundation and accelerating sustainable growth as biologics and generics converge under one roof.
For Biocon, this is more than a change at the top—it is a full-spectrum reset, with execution now the only metric that matters.
